A genomic test being developed by a Charlottesville company can predict a patient’s risk of developing severe COVID-19, new research from UVA Health suggests. That information could help doctors identify patients at high risk for poor outcomes and quickly begin tailored treatment.
A monoclonal antibody used to treat asthma and eczema can improve survival for patients with moderate to severe COVID-19, a clinical trial at UVA Health suggests.
As COVID-19 case counts continue to decline, additional visitation will be permitted at University of Virginia Medical Center inpatient units, Emergency Department, outpatient clinics and outpatient procedural areas effective Thursday, March 3. The changes also apply to UVA’s Transitional Care Hospital.
With scientists counting on our immune systems’ “memory” to provide long-term protection against severe COVID-19, School of Medicine researchers and their collaborators have shed light on how one such type of “memory” cells mounts powerful defenses against subsequent infections.
UVA Health has joined a nationwide study evaluating two repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19.
UVA Health is now scheduling appointments for the Pfizer COVID-19 vaccine for children 5-11 years old at its Pediatric Community Vaccination Center, with the first appointments available Monday, Nov. 8.